Catheter ablation was significantly associated with reduced ventricular tachycardia recurrence at 1 year in patients with biopsy-proven myocarditis (P=0.048), except in acute cases.
Cohort (n=50)
Yes
Does catheter ablation reduce ventricular tachycardia recurrence in patients with biopsy-proven myocarditis?
Catheter ablation is associated with reduced ventricular tachycardia recurrence at 1 year in patients with biopsy-proven myocarditis, though this benefit is not observed during the acute stage of the disease.
p-value: p=0.048
Background: Catheter ablation (CA) is increasingly recognized as an effective treatment for ventricular tachycardia (VT) in myocarditis patients, although current evidence is based on less robust data. Objectives: The purpose of this study was to confirm CA's efficacy in reducing VT recurrence and to identify arrhythmic risk factors in biopsy-proven myocarditis patients. Methods: In this dual-center, retrospective study, we included 50 patients with biopsy-proven myocarditis and VT. They were divided into 2 groups: CA (n = 23) and non-CA (n = 27), with the primary endpoint being VT recurrence at 1-year follow-up. Results: 0.048). Conclusions: CA is significantly associated with reduced VT recurrence in biopsy-proven myocarditis, albeit this association is not observed in cases of acute myocarditis. The acute stage of myocarditis is independently associated with an increased risk of VT recurrence.
Li et al. (Tue,) conducted a cohort in Biopsy-proven myocarditis and ventricular tachycardia (n=50). Catheter ablation vs. No catheter ablation (non-CA) was evaluated on Ventricular tachycardia recurrence (p=0.048). Catheter ablation was significantly associated with reduced ventricular tachycardia recurrence at 1 year in patients with biopsy-proven myocarditis (P=0.048), except in acute cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: